← All stocks

Lyell Immunopharma, Inc.

LYEL Net buying
CIK 0001806952 #3374 in the set updated 17 Sep 2026
Bought (12 mo)
$25.00M
out of their own pocket, the only kind of buying there is
Sold (12 mo)
$604.59K
$274.30 on a plan · $0.00 straight out of an exercise
Sold at will
$604.31K
26 of 28 sales
Net
+$24.40M
+$24.40M against sales at will

By person

14 insiders · 30 transactions
Insider
Role
Bought
Sold
Net
Holding
Worth
Change
ARCH Venture Fund XIII, L.P. entity
10% owner
$12.50M (1)
+$12.50M
1,426,528
$18.12M
+52.0%
ARCH Venture Partners IX, LLC entity
10% owner
$12.50M (1)
+$12.50M
1,426,528
$18.12M
+52.0%
Seely Lynn
President and CEO
$353.08K (6)
−$353.08K
63,899
$811.52K
Bulis Veronica Sanchez
VP, Corporate Controller
$96.91K (6)
−$96.91K
14,799
$187.95K
+56.6%
Lee Gary K.
Chief Scientific Officer
$71.69K (6)
−$71.69K
16,220
$205.99K
Hill Stephen J.
Chief Operating Officer
$51.29K (6)
−$51.29K
16,816
$213.56K
Shook David
Chief Medical Officer
$31.34K (2)
−$31.34K
20,423
$259.37K
+1,942%
Innovative Cellular Therapeutics Holdings Ltd entity
10% owner
$274.30 (2) scheduled
−$274.30
2,818,980
$35.80M
−7.4%
Klausner Richard
Director
843,365
$10.71M
+23.1%
Newton Charles W.
Chief Financial Officer
215,306
$2.73M
Ramachandra Sumant
Director
200,000
$2.54M
Lang Matthew
Chief Business Officer
162,500
$2.06M
+225.0%
BRAWLEY OTIS W
Director
35,640
$452.63K
Aguirre Jarrad Mattieu
Chief Medical Officer
20,279
$257.54K
0.0%

No percentages here. This company's share count has moved by a factor of 15.4 over the window, from 19,211,202 to 295,228,868 shares. A split, a merger or a large issue changes what the company is, and a holding measured at one point in that run is not a fraction of it at another.

Insider
Date
Role
Action
Shares
Price
Amount
Shook David
10 Sep 2026
Chief Medical Officer
Sell
500
$12.70
$6.35K
Lee Gary K.
21 Aug 2026
Chief Scientific Officer
Sell
1,457
$15.54
$22.64K
Hill Stephen J.
21 Aug 2026
Chief Operating Officer
Sell
989
$15.54
$15.37K
Seely Lynn
21 Aug 2026
President and CEO
Sell
9,589
$15.54
$149.01K
Seely Lynn
10 Aug 2026
President and CEO
Sell
390
$14.34
$5.59K
Hill Stephen J.
10 Aug 2026
Chief Operating Officer
Sell
89
$14.34
$1.28K
Lee Gary K.
10 Aug 2026
Chief Scientific Officer
Sell
131
$14.34
$1.88K
Bulis Veronica Sanchez
10 Aug 2026
VP, Corporate Controller
Sell
621
$14.34
$8.91K
Innovative Cellular Therapeutics Holdings Ltd
17 Jul 2026
10% owner
Sold on a plan
10
$13.70
$137.00
Innovative Cellular Therapeutics Holdings Ltd
16 Jul 2026
10% owner
Sold on a plan
10
$13.73
$137.30
Shook David
10 Jun 2026
Chief Medical Officer
Sell
1,977
$12.64
$24.99K
Bulis Veronica Sanchez
11 May 2026
VP, Corporate Controller
Sell
217
$18.91
$4.10K
Hill Stephen J.
11 May 2026
Chief Operating Officer
Sell
89
$18.92
$1.68K
Lee Gary K.
11 May 2026
Chief Scientific Officer
Sell
130
$18.92
$2.46K
Seely Lynn
11 May 2026
President and CEO
Sell
388
$18.91
$7.34K
ARCH Venture Fund XIII, L.P.
6 Mar 2026
10% owner
Buy indirect
488,090
$25.61
$12.50M
ARCH Venture Partners IX, LLC
6 Mar 2026
10% owner
Buy indirect
488,090
$25.61
$12.50M
Lee Gary K.
11 Feb 2026
Chief Scientific Officer
Sell
1,671
$23.39
$39.08K
Hill Stephen J.
11 Feb 2026
Chief Operating Officer
Sell
1,236
$23.39
$28.91K
Seely Lynn
11 Feb 2026
President and CEO
Sell
7,455
$23.39
$174.37K
Bulis Veronica Sanchez
10 Feb 2026
VP, Corporate Controller
Sell
254
$23.12
$5.87K
Seely Lynn
10 Feb 2026
President and CEO
Sell
438
$23.12
$10.13K
Lee Gary K.
10 Feb 2026
Chief Scientific Officer
Sell
147
$23.12
$3.40K
Hill Stephen J.
10 Feb 2026
Chief Operating Officer
Sell
109
$23.12
$2.52K
Bulis Veronica Sanchez
30 Dec 2025
VP, Corporate Controller
Sell
936
$32.32
$30.25K
Bulis Veronica Sanchez
24 Dec 2025
VP, Corporate Controller
Sell
1,136
$38.67
$43.93K
Hill Stephen J.
10 Nov 2025
Chief Operating Officer
Sell
95
$16.12
$1.53K
Lee Gary K.
10 Nov 2025
Chief Scientific Officer
Sell
138
$16.16
$2.23K
Bulis Veronica Sanchez
10 Nov 2025
VP, Corporate Controller
Sell
239
$16.10
$3.85K
Seely Lynn
10 Nov 2025
President and CEO
Sell
412
$16.11
$6.64K

What was left out

Form 4 filings counted 47
Amendments (4/A) skipped 0
Filings about a different issuer 0
Unreadable filings 0
Joint filings 2
Sales on a Rule 10b5-1 plan 2
Sales straight out of an exercise 0
Sales at will 26
Transactions with no price 0
Shares from compensation/vesting 261,750
History held since 23 Jun 2021